MIRA Pharmaceuticals Inc. (MIRA) Financial Statements (2026 and earlier)

Company Profile

Business Address 1200 BRICKELL AVENUE
MIAMI, FL 33131
State of Incorp. FL
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments11,030,0207,535,905730,4751,206,2852,832,9314,144,560
Cash and cash equivalent6,346,9212,641,539730,4751,206,2852,832,9314,144,560
Short-term investments4,683,0994,894,366    
Prepaid expense28,14661,936102,404158,61454,72986,572
Total current assets:11,058,1667,597,841832,8791,364,8992,887,6604,231,132
Noncurrent Assets
Other undisclosed noncurrent assets35,43935,43935,43935,43935,43935,439
Total noncurrent assets:35,43935,43935,43935,43935,43935,439
TOTAL ASSETS:11,093,6057,633,280868,3181,400,3382,923,0994,266,571
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:129,20383,926298,459106,173723,349692,833
Accounts payable129,20383,926298,459100,673  
Accrued liabilities    5,500  
Other undisclosed accounts payable and accrued liabilities     723,349692,833
Other liabilities 572,865     
Other undisclosed current liabilities      
Total current liabilities:702,06883,926298,459106,173723,349692,833
Noncurrent Liabilities
Total liabilities:702,06883,926298,459106,173723,349692,833
Equity
Equity, attributable to parent10,391,5377,549,354569,8591,294,1652,199,7503,573,738
Common stock4,1943,9511,7391,6821,6561,627
Additional paid in capital49,967,54941,142,28833,027,33232,213,98331,335,81530,310,136
Accumulated deficit(39,580,206)(33,596,885)(32,459,212)(30,921,500)(29,137,721)(26,738,025)
Total equity:10,391,5377,549,354569,8591,294,1652,199,7503,573,738
TOTAL LIABILITIES AND EQUITY:11,093,6057,633,280868,3181,400,3382,923,0994,266,571

Income Statement (P&L) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Operating expenses(5,824,827)(1,316,985)(1,546,100)(1,805,200)(2,437,801)(2,081,619)
Operating loss:(5,824,827)(1,316,985)(1,546,100)(1,805,200)(2,437,801)(2,081,619)
Nonoperating income (expense)(158,494)179,312(107)   
Other nonoperating expense (12,441)(107)   
Net loss:(5,983,321)(1,137,673)(1,546,207)(1,805,200)(2,437,801)(2,081,619)
Other undisclosed net income attributable to parent   8,49521,42138,10537,752
Net loss attributable to parent:(5,983,321)(1,137,673)(1,537,712)(1,783,779)(2,399,696)(2,043,867)
Preferred stock dividends and other adjustments  (21,556,821)    
Net loss available to common stockholders, diluted:(5,983,321)(22,694,494)(1,537,712)(1,783,779)(2,399,696)(2,043,867)

Comprehensive Income (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(5,983,321)(1,137,673)(1,546,207)(1,805,200)(2,437,801)(2,081,619)
Comprehensive loss, net of tax, attributable to parent:(5,983,321)(1,137,673)(1,546,207)(1,805,200)(2,437,801)(2,081,619)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: